|
GB8308235D0
(en)
|
1983-03-25 |
1983-05-05 |
Celltech Ltd |
Polypeptides
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
|
JP3101690B2
(ja)
|
1987-03-18 |
2000-10-23 |
エス・ビィ・２・インコーポレイテッド |
変性抗体の、または変性抗体に関する改良
|
|
DE69120146T2
(de)
|
1990-01-12 |
1996-12-12 |
Cell Genesys Inc |
Erzeugung xenogener antikörper
|
|
DE69133557D1
(de)
|
1990-08-29 |
2007-03-15 |
Pharming Intellectual Pty Bv |
Homologe rekombination in säugetier-zellen
|
|
US5565332A
(en)
|
1991-09-23 |
1996-10-15 |
Medical Research Council |
Production of chimeric antibodies - a combinatorial approach
|
|
US6180377B1
(en)
|
1993-06-16 |
2001-01-30 |
Celltech Therapeutics Limited |
Humanized antibodies
|
|
US6130364A
(en)
|
1995-03-29 |
2000-10-10 |
Abgenix, Inc. |
Production of antibodies using Cre-mediated site-specific recombination
|
|
US6410690B1
(en)
|
1995-06-07 |
2002-06-25 |
Medarex, Inc. |
Therapeutic compounds comprised of anti-Fc receptor antibodies
|
|
DK1666591T3
(da)
|
1995-06-29 |
2011-05-23 |
Immunex Corp |
Cytokin der inducerer apoptose
|
|
ATE342729T1
(de)
|
1997-01-15 |
2006-11-15 |
Phoenix Pharmacologics Inc |
Modifizierter tumor-nekrosefaktor
|
|
PT1012274E
(pt)
|
1997-01-28 |
2007-08-14 |
Craig A Rosen |
Receptor 4 contendo um domínio de morte (dm4; receptor de morte 4), membro da super-família do ftn e ligação a liart (ap02)
|
|
US6072047A
(en)
|
1997-02-13 |
2000-06-06 |
Immunex Corporation |
Receptor that binds trail
|
|
WO1999000423A1
(en)
|
1997-06-26 |
1999-01-07 |
Immunex Corporation |
Protein that binds trail
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
|
US6329148B1
(en)
|
1999-02-16 |
2001-12-11 |
The Board Of Trustees Of The Leland Stanford University |
Combined therapy of diterpenoid triepoxides and death domain receptor ligands for synergistic killing of tumor cells
|
|
US7550143B2
(en)
|
2005-04-06 |
2009-06-23 |
Ibc Pharmaceuticals, Inc. |
Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
|
|
US7534866B2
(en)
|
2005-10-19 |
2009-05-19 |
Ibc Pharmaceuticals, Inc. |
Methods and compositions for generating bioactive assemblies of increased complexity and uses
|
|
BR0010750A
(pt)
|
1999-05-17 |
2002-02-26 |
Conjuchem Inc |
Peptìdeos insulinotrópicos de longa duração
|
|
US7160924B2
(en)
|
2002-07-19 |
2007-01-09 |
The General Hospital Corporation |
Protein conjugates with a water-soluble biocompatible, biodegradable polymer
|
|
EP1223961A4
(en)
|
1999-09-30 |
2005-10-05 |
Univ Pennsylvania |
"TRAIL" AS INHIBITOR OF AUTOIMMUNE INFLAMMATION AND CELL CYCLE PROGRESSION
|
|
IL136156A0
(en)
|
2000-05-16 |
2001-05-20 |
Compugen Ltd |
Sequences of trail variants
|
|
US20040005314A1
(en)
|
2001-07-27 |
2004-01-08 |
Enrique Escandon |
Apo-2l receptor agonist and cpt-11 synergism
|
|
KR100396983B1
(ko)
|
2000-07-29 |
2003-09-02 |
이강춘 |
고반응성의 가지 달린 고분자 유도체 및 고분자와 단백질또는 펩타이드의 접합체
|
|
JP2004508420A
(ja)
|
2000-09-18 |
2004-03-18 |
アイデック ファーマスーティカルズ コーポレイション |
Ｂ細胞枯渇抗体／免疫調節性抗体の組合せを用いて自己免疫疾患を治療するための併用療法
|
|
KR20020056565A
(ko)
|
2000-12-29 |
2002-07-10 |
황규언 |
인간유래 세포 소멸 인자와 그 수용체의 결합체인ＴＲＡＩＬ-ｓＤＲ5 결합체의 결정화에 의한 3차원 구조및 ＴＲＡＩＬ 결실 돌연변이 단백질
|
|
US20020169123A1
(en)
|
2001-02-27 |
2002-11-14 |
The Trustees Of The University Of Pennsylvania |
Regulating apoptosis in TRAIL-resistant cancer cells, while protecting normal, non-cancerous cells
|
|
KR100521526B1
(ko)
|
2001-07-10 |
2005-10-13 |
캐논 가부시끼가이샤 |
폴리하이드록시알카노에이트로 이루어진 입상 구조체 및그 제조방법
|
|
DE10144252A1
(de)
|
2001-08-31 |
2003-03-27 |
Fraunhofer Ges Forschung |
Nanopartikel mit daran immobilisiertem biologisch aktivem TNF
|
|
EP1501866A4
(en)
|
2001-10-02 |
2006-02-08 |
Genentech Inc |
VARIANTS OF THE LIGAND APO-2 AND USES THEREOF
|
|
US6908963B2
(en)
|
2001-10-09 |
2005-06-21 |
Nektar Therapeutics Al, Corporation |
Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
|
|
US7906118B2
(en)
|
2005-04-06 |
2011-03-15 |
Ibc Pharmaceuticals, Inc. |
Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology
|
|
EP2500032A1
(en)
|
2002-06-24 |
2012-09-19 |
Genentech, Inc. |
APO-2 ligand/trail variants and uses thereof
|
|
JP2006501820A
(ja)
|
2002-09-06 |
2006-01-19 |
バイエル・フアーマシユーチカルズ・コーポレーシヨン |
修飾ｇｌｐ−１受容体アゴニストおよびそれらの薬理学的使用法
|
|
US20050203142A1
(en)
|
2002-10-24 |
2005-09-15 |
Zeldis Jerome B. |
Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
|
|
JP2006506985A
(ja)
|
2002-10-30 |
2006-03-02 |
ファイザー・プロダクツ・インク |
コンパニオンアニマルのガンを診断および治療するための方法および組成物
|
|
GB2401040A
(en)
|
2003-04-28 |
2004-11-03 |
Chugai Pharmaceutical Co Ltd |
Method for treating interleukin-6 related diseases
|
|
EP1754713B1
(en)
|
2003-05-09 |
2009-02-25 |
Genentech, Inc. |
Apo2L (Trail) receptor binding peptides and uses thereof
|
|
US7186699B2
(en)
|
2003-06-03 |
2007-03-06 |
Cell Genesys, Inc. |
Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
|
|
US7795404B1
(en)
|
2003-08-08 |
2010-09-14 |
Five Prime Therapeutics, Inc. |
Human soluble notch receptor ligands
|
|
GB0328261D0
(en)
|
2003-12-05 |
2004-01-07 |
Univ Groningen |
Improved cytokine design
|
|
US20110020273A1
(en)
|
2005-04-06 |
2011-01-27 |
Ibc Pharmaceuticals, Inc. |
Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof
|
|
US8003111B2
(en)
|
2005-04-06 |
2011-08-23 |
Ibc Pharmaceuticals, Inc. |
Dimeric alpha interferon pegylated site-specifically shows enhanced and prolonged efficacy in vivo
|
|
US8034352B2
(en)
|
2005-04-06 |
2011-10-11 |
Ibc Pharmaceuticals, Inc. |
Tetrameric cytokines with improved biological activity
|
|
ES2246694B1
(es)
|
2004-04-29 |
2007-05-01 |
Instituto Cientifico Y Tecnologico De Navarra, S.A. |
Nanoparticulas pegiladas.
|
|
US20080199423A1
(en)
|
2004-06-18 |
2008-08-21 |
Genentech, Inc. |
Methods of Using Apo2l Receptor Agonists and Ink Cell Activators
|
|
US8143380B2
(en)
|
2004-07-08 |
2012-03-27 |
Amgen Inc. |
Therapeutic peptides
|
|
US20060046961A1
(en)
*
|
2004-09-02 |
2006-03-02 |
Mckay William F |
Controlled and directed local delivery of anti-inflammatory compositions
|
|
JP2008513367A
(ja)
|
2004-09-08 |
2008-05-01 |
ジェネンテック・インコーポレーテッド |
デスレセプターリガンド及びｃｄ２０抗体の使用方法
|
|
JP2008516621A
(ja)
|
2004-10-18 |
2008-05-22 |
ノボ ノルディスク アクティーゼルスカブ |
成長ホルモン結合体
|
|
US8029783B2
(en)
*
|
2005-02-02 |
2011-10-04 |
Genentech, Inc. |
DR5 antibodies and articles of manufacture containing same
|
|
US20060188498A1
(en)
*
|
2005-02-18 |
2006-08-24 |
Genentech, Inc. |
Methods of using death receptor agonists and EGFR inhibitors
|
|
EP1695717A1
(en)
|
2005-02-23 |
2006-08-30 |
Ludwig-Maximilians-Universität |
Transport of nano-and macromolecular structures into cytoplasm and nucleus of cells
|
|
US20060228352A1
(en)
|
2005-02-24 |
2006-10-12 |
Schoenberger Stephen P |
TRAIL and methods of modulating T cell activity and adaptive immune responses using TRAIL
|
|
CA2604032C
(en)
|
2005-04-06 |
2017-08-22 |
Ibc Pharmaceuticals, Inc. |
Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
|
|
AU2006232310B9
(en)
|
2005-04-06 |
2011-07-21 |
Ibc Pharmaceuticals, Inc. |
Improved stably tethered structures of defined compositions with multiple functions or binding specificities
|
|
US8158129B2
(en)
|
2005-04-06 |
2012-04-17 |
Ibc Pharmaceuticals, Inc. |
Dimeric alpha interferon PEGylated site-specifically shows enhanced and prolonged efficacy in vivo
|
|
EP1745802A1
(en)
|
2005-07-20 |
2007-01-24 |
Kreatech Biotechnology B.V. |
Method of conjugating therapeutic compounds to cell targeting moieties via metal complexes
|
|
CA2607056C
(en)
|
2005-10-19 |
2015-11-24 |
Ibc Pharmaceuticals, Inc. |
Methods and compositions for generating bioactive assemblies of increased complexity and uses
|
|
GB0524316D0
(en)
|
2005-11-29 |
2006-01-04 |
Medical Res Council |
Tumour necrosis factor-related apoptosis-inducing ligands (TRAILs)
|
|
EP2364735A3
(en)
|
2005-12-16 |
2012-04-11 |
Nektar Therapeutics |
Branched PEG conjugates of GLP-1
|
|
EP2441846A3
(en)
|
2006-01-09 |
2012-07-25 |
The Regents Of the University of California |
Immunostimulatory combinations of TNFRSF, TLR, NLR, RHR, purinergic receptor, and cytokine receptor agoinsts for vaccines and tumor immunotherapy
|
|
KR100784485B1
(ko)
|
2006-01-18 |
2007-12-11 |
한국과학기술연구원 |
생분해성 온도 감응성 폴리포스파젠계 하이드로젤, 그의제조방법 및 그의 용도
|
|
WO2007102690A1
(en)
|
2006-03-06 |
2007-09-13 |
Postech Foundation |
Vector including the codon-optimized dna cassette for producing secretory recombinant dodecamer trail
|
|
KR100746962B1
(ko)
|
2006-04-04 |
2007-08-07 |
한국과학기술연구원 |
온도 감응성 포스파젠계 고분자-생리 활성 물질 복합체,그의 제조방법 및 그의 용도
|
|
US9283260B2
(en)
|
2006-04-21 |
2016-03-15 |
Amgen Inc. |
Lyophilized therapeutic peptibody formulations
|
|
CN101074261A
(zh)
*
|
2006-04-30 |
2007-11-21 |
北京同为时代生物技术有限公司 |
Trail受体1和/或trail受体2特异性抗体及其应用
|
|
US8080248B2
(en)
|
2006-06-02 |
2011-12-20 |
Regeneron Pharmaceuticals, Inc. |
Method of treating rheumatoid arthritis with an IL-6R antibody
|
|
KR100886783B1
(ko)
|
2006-06-12 |
2009-03-04 |
성균관대학교산학협력단 |
N-말단이 수식된 peg-trail 결합체, 이의 제조방법 및 이의 용도
|
|
KR101433971B1
(ko)
|
2006-06-20 |
2014-08-25 |
제넨테크, 인크. |
클라트린-경로 성분의 단편을 검출함으로써 세포자멸을 관찰하기 위한 방법 및 물질
|
|
WO2007147600A2
(en)
|
2006-06-21 |
2007-12-27 |
Apogenix Gmbh |
Differential il-4 and/or il-10 cytokine expression in human cancer
|
|
WO2008088582A2
(en)
|
2006-08-04 |
2008-07-24 |
Mayo Foundation For Medical Education And Research |
Methods and materials related to trail isoforms
|
|
CA2663047A1
(en)
|
2006-09-06 |
2008-03-13 |
Phase Bioscience, Inc. |
Therapeutic elastin-like polypeptide (elp) fusion proteins
|
|
AU2009233925B2
(en)
|
2006-12-05 |
2014-03-13 |
Ibc Pharmaceuticals, Inc. |
Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology
|
|
WO2008120832A1
(en)
|
2007-03-30 |
2008-10-09 |
Industry-Academic Cooperation Foundation, Yonsei University |
Human neural stem cell secreting a smac, preparation method and use thereof
|
|
WO2008130066A1
(en)
|
2007-04-20 |
2008-10-30 |
Kang Choon Lee |
Mono modified exendin with polyethylene glycol or its derivatives and uses thereof
|
|
KR100968591B1
(ko)
|
2007-06-14 |
2010-07-08 |
한국과학기술연구원 |
약물전달용 폴리포스파젠계 하이드로젤, 그의 제조방법 및그의 용도
|
|
AU2008279618B2
(en)
|
2007-07-25 |
2014-05-22 |
Alexion Pharmaceuticals, Inc. |
Methods and compositions for treating autoimmune disease
|
|
CA2695991A1
(en)
|
2007-08-09 |
2009-02-12 |
Daiichi Sankyo Company, Limited |
Immunoliposome inducing apoptosis into cell expressing death domain-containing receptor
|
|
US8440787B2
(en)
|
2007-10-23 |
2013-05-14 |
Nektar Therapeutics |
Hydroxyapatite-targeting multiarm polymers and conjugates made therefrom
|
|
US8633297B2
(en)
|
2007-10-31 |
2014-01-21 |
Medimmune, Llc |
Protein scaffolds
|
|
GB0723059D0
(en)
|
2007-11-23 |
2008-01-02 |
Nat Univ Ireland |
Improved cytokine design
|
|
US20090203671A1
(en)
|
2007-11-27 |
2009-08-13 |
Abbott Laboratories |
Method of treating cancer
|
|
GB0724532D0
(en)
|
2007-12-17 |
2008-01-30 |
Nat Univ Ireland |
Trail variants for treating cancer
|
|
CL2009001191A1
(es)
|
2008-05-14 |
2010-07-02 |
Genentech Inc |
Uso del peptido apo2l/trail porque sirve para preparar un medicamento para tratar el cancer de pulmon y el linfoma de hodkin.
|
|
US20100068302A1
(en)
|
2008-09-17 |
2010-03-18 |
Traslational Cancer Drugs Pharma, S.L. |
Methods and compositions for the treatment of cancer
|
|
JP2012504969A
(ja)
|
2008-10-10 |
2012-03-01 |
アナフォア インコーポレイテッド |
Ｔｒａｉｌ−ｒ１及びｔｒａｉｌ−ｒ２に結合するポリペプチド
|
|
US20120021995A1
(en)
|
2008-10-10 |
2012-01-26 |
Anaphore, Inc. |
Polypeptides that Bind TRAIL-R1 and TRAIL-R2
|
|
GB0818649D0
(en)
|
2008-10-10 |
2008-11-19 |
Nat Univ Ireland |
Treatment of proliferative disorders with trail
|
|
ES2610356T3
(es)
|
2009-02-03 |
2017-04-27 |
Amunix Operating Inc. |
Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos
|
|
ES3000111T3
(en)
|
2009-02-13 |
2025-02-27 |
Immunomedics Inc |
Intermediates for preparing conjugates with an intracellularly-cleavable linkage
|
|
CN101870728A
(zh)
|
2009-04-23 |
2010-10-27 |
派格生物医药(苏州)有限公司 |
新型Exendin变体及其缀合物
|
|
CA2772572A1
(en)
|
2009-08-31 |
2011-03-03 |
Ibc Pharmaceuticals, Inc. |
Bispecific immunocytokine dock-and-lock (dnl) complexes and therapeutic use thereof
|
|
WO2011079293A1
(en)
|
2009-12-23 |
2011-06-30 |
Ambrx, Inc |
Tumor necrosis factor-related apoptosis inducing ligand polypeptides and their uses
|
|
EP2519260A2
(en)
|
2009-12-31 |
2012-11-07 |
Deutsches Krebsforschungszentrum |
Novel modulators of trail signalling
|
|
WO2011106707A2
(en)
*
|
2010-02-26 |
2011-09-01 |
Human Genome Sciences, Inc. |
Antibodies that specifically bind to dr3
|
|
WO2011130324A1
(en)
|
2010-04-13 |
2011-10-20 |
Medimmune, Llc |
Fibronectin type iii domain-based multimeric scaffolds
|
|
US8461311B2
(en)
|
2010-06-08 |
2013-06-11 |
Washington University |
TRAIL trimers, methods and uses therefor
|
|
KR101209266B1
(ko)
|
2010-06-30 |
2012-12-06 |
한국과학기술연구원 |
생분해성 및 온도 감응성 폴리포스파젠계 자성 고분자, 그의 제조 방법 및 용도
|
|
PH12013500845A1
(en)
|
2010-10-29 |
2013-06-24 |
Daiichi Sankyo Co Ltd |
Novel anti-dr5 antibody
|
|
EP2468764A1
(en)
|
2010-12-24 |
2012-06-27 |
Rijksuniversiteit te Groningen |
TNF family ligand variants
|
|
US9428565B2
(en)
|
2011-01-31 |
2016-08-30 |
The General Hospital Corporation |
Treatment and bioluminescent visualization using multimodal TRAIL molecules
|
|
CA2828405A1
(en)
|
2011-02-28 |
2012-09-07 |
Istituto Di Ricovero E Cura A Carattere Scientifico Materno-Infantile Bu Rlo Garofolo - Ospedale Di Alta Specializzazione E Di Rilievo Nazionale |
Apoptosis-inducing molecules and uses therefor
|
|
US20140079722A1
(en)
|
2011-03-09 |
2014-03-20 |
Centrose, Llc |
Extracellular targeted drug conjugates
|
|
CN103561771B
(zh)
|
2011-03-17 |
2019-01-04 |
伯明翰大学 |
重新定向的免疫治疗
|
|
US20130101553A1
(en)
|
2011-04-18 |
2013-04-25 |
The Regents Of The University Of California |
Inducing inactivation of fibrogenic myofibroblasts
|
|
EP3679934B1
(en)
|
2011-04-29 |
2024-06-05 |
The Penn State Research Foundation |
Small molecule trail gene induction by normal and tumor cells as an anticancer therapy
|
|
EP2704735A1
(en)
|
2011-05-03 |
2014-03-12 |
Genentech, Inc. |
Vascular disruption agents and uses thereof
|
|
FI20115640A0
(fi)
|
2011-06-22 |
2011-06-22 |
Turun Yliopisto |
Yhdistelmähoito
|
|
US8586020B2
(en)
|
2011-06-30 |
2013-11-19 |
Korea Institute Of Science And Technology |
Poly(organophosphazene) composition for biomaterials
|
|
CN103747807B
(zh)
|
2011-07-05 |
2016-12-07 |
比奥阿赛斯技术有限公司 |
P97‑抗体缀合物和使用方法
|
|
CN111592601A
(zh)
|
2011-07-06 |
2020-08-28 |
江苏靶标生物医药研究所有限公司 |
一种肿瘤靶向性肿瘤坏死因子相关凋亡配体变体及其应用
|
|
CN102898526A
(zh)
|
2011-07-28 |
2013-01-30 |
山东先声麦得津生物制药有限公司 |
一种肿瘤坏死因子相关凋亡诱导配体融合蛋白及其制备和应用
|
|
GB201203442D0
(en)
|
2012-02-28 |
2012-04-11 |
Univ Birmingham |
Immunotherapeutic molecules and uses
|
|
JP6219923B2
(ja)
|
2012-03-28 |
2017-10-25 |
アムジェン インコーポレイテッド |
Ｄｒ５受容体アゴニストの組み合わせ
|
|
WO2013156054A1
(en)
|
2012-04-16 |
2013-10-24 |
Universität Stuttgart |
The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity
|
|
EP3473708B1
(en)
|
2012-07-24 |
2021-01-27 |
The General Hospital Corporation |
Oncolytic virus therapy for resistant tumors
|
|
US20150038511A1
(en)
|
2012-08-09 |
2015-02-05 |
Celgene Corporation |
Treatment of immune-related and inflammatory diseases
|
|
CA2883356A1
(en)
|
2012-08-30 |
2014-03-06 |
Turun Yliopisto |
Method of selecting individualized brain cancer therapy
|
|
WO2014035474A1
(en)
|
2012-08-30 |
2014-03-06 |
The General Hospital Corporation |
Compositions and methods for treating cancer
|
|
MA37946B1
(fr)
|
2012-09-20 |
2018-09-28 |
Morphosys Ag |
Utilisation d’un anticorps anti-gm-csf pour le traitement de la polyarthrite rhumatoïde
|
|
US20140134647A1
(en)
|
2012-11-01 |
2014-05-15 |
La Jolla Institute For Allergy And Immunology |
Novel crystal structure and ligand binding sites of trail receptor
|
|
CA2891280C
(en)
|
2012-11-24 |
2018-03-20 |
Hangzhou Dac Biotech Co., Ltd. |
Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
|
|
WO2014082083A1
(en)
|
2012-11-26 |
2014-05-30 |
Caris Science, Inc. |
Biomarker compositions and methods
|
|
WO2014121093A1
(en)
*
|
2013-01-31 |
2014-08-07 |
Thomas Jefferson University |
Fusion proteins that facilitate cancer cell destruction
|
|
JP6177937B2
(ja)
|
2013-02-13 |
2017-08-09 |
エイジェンシー フォー サイエンス，テクノロジー アンド リサーチ |
活性薬剤の放出のためのポリマーシステム
|
|
WO2015010615A1
(zh)
|
2013-07-23 |
2015-01-29 |
四川大学华西医院 |
一种重组trail蛋白及其制备方法和用途
|
|
EP3041846B1
(en)
|
2013-09-02 |
2018-11-07 |
Hangzhou Dac Biotech Co., Ltd |
Novel cytotoxic agents for conjugation of drugs to cell binding molecule
|
|
WO2015037000A1
(en)
|
2013-09-11 |
2015-03-19 |
Compugen Ltd |
Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases
|
|
PL222795B1
(pl)
|
2013-12-22 |
2016-09-30 |
Univ Warszawski |
Rekombinowane białko fuzyjne ProSTAT do zastosowania w leczeniu
|
|
US10464955B2
(en)
|
2014-02-28 |
2019-11-05 |
Hangzhou Dac Biotech Co., Ltd. |
Charged linkers and their uses for conjugation
|
|
WO2015138638A1
(en)
*
|
2014-03-11 |
2015-09-17 |
Theraly Pharmaceuticals, Inc. |
Long acting trail receptor agonists for treatment of autoimmune diseases
|
|
US9901620B2
(en)
|
2014-04-21 |
2018-02-27 |
Theraly Pharmaceuticals, Inc. |
Trail receptor agonists for treatment of fibrotic disease
|
|
PL3145530T3
(pl)
*
|
2014-04-21 |
2021-10-18 |
D&D Pharmatech Inc. |
Agonisty receptora trail w leczeniu chorób zwłóknieniowych
|
|
US10975112B2
(en)
|
2015-06-16 |
2021-04-13 |
Hangzhou Dac Biotech Co., Ltd. |
Linkers for conjugation of cell-binding molecules
|